Therapeutic Drug Monitoring — MCQs

10 questions

In which phase of drug clinical trials is post-marketing surveillance included?

A patient given digoxin started having side effects like nausea and vomiting. The serum concentration of digoxin was 4 ng/mL. The plasma therapeutic range is 1-2 ng/mL. If the half-life of digoxin is 40 hours, how long should one wait before resuming the treatment?

Variation in sensitivity of response to different doses of a drug in different individuals is obtained from?

A patient on digoxin therapy presents with atrial fibrillation and controlled ventricular rate. Upon evaluation, the patient's serum digoxin levels are elevated compared to previous values. Which of the following concomitant medications is most likely to have contributed to the enhanced digoxin toxicity?

Which study design is most effective for investigating rare adverse effects of a drug?

At toxic doses, zero-order kinetics is seen in which of the following substances?

Lidocaine is used in a loading dose for the treatment of arrhythmias. The loading dose of this drug depends upon which of the following factors?

Therapeutic index of a drug is an indicator of its:

Nystagmus is associated with all except:

Q10

Which one of the following causes low-volume erythrocytosis?

Therapeutic Drug Monitoring Indian Medical PG Practice Questions and MCQs

Question 1: In which phase of drug clinical trials is post-marketing surveillance included?

A. Phase II
B. Phase III
C. Phase IV (Correct Answer)
D. Phase I

Explanation: ***Phase IV*** - **Phase IV** clinical trials occur after a drug has been approved for marketing and involves **post-marketing surveillance** to monitor the drug's safety and effectiveness in the general population. - This phase identifies **rare or long-term side effects** that may not have been observed in earlier, smaller trials. *Phase II* - **Phase II** trials assess the drug's **effectiveness** and side effects in a larger group of patients (typically 100-300 people) with the condition [2],[3]. - These trials establish the optimal **dosage** and regimen [2]. *Phase III* - **Phase III** trials are large-scale studies (hundreds to thousands of patients) that compare the new drug to an existing treatment or placebo to confirm its **efficacy** and monitor adverse effects [4]. - Successful completion of this phase is generally required for **regulatory approval**. *Phase I* - **Phase I** trials are the first stage of testing in humans, usually involving a small group of healthy volunteers (20-100 people) to evaluate **safety**, dosage range, and pharmacokinetics [1]. - The primary goal is to determine if the drug is safe to proceed to further studies.

Question 2: A patient given digoxin started having side effects like nausea and vomiting. The serum concentration of digoxin was 4 ng/mL. The plasma therapeutic range is 1-2 ng/mL. If the half-life of digoxin is 40 hours, how long should one wait before resuming the treatment?

A. 120 hours
B. 140-180 hours
C. 1 half-life (40 hours)
D. 80 hours (Correct Answer)

Explanation: ***80 hours (2 half-lives)***- Current digoxin level is **4 ng/mL**, which is **twice the upper therapeutic limit** (2 ng/mL), causing toxicity with nausea and vomiting [1]- After **1 half-life (40 hours)**: concentration reduces to 2 ng/mL (upper therapeutic limit) [2]- After **2 half-lives (80 hours)**: concentration reduces to 1 ng/mL (mid-therapeutic range) [2]- **Clinical rationale**: While 2 ng/mL is technically within range, waiting for 2 half-lives ensures the level is comfortably in the **middle of the therapeutic window** (1 ng/mL), providing a **safer margin** before resuming treatment in a patient who just experienced toxicity- This conservative approach minimizes risk of recurrent toxicity, especially important given the patient's recent symptoms at 4 ng/mL*1 half-life (40 hours)*- After 1 half-life, digoxin level would be 2 ng/mL, which is at the **upper limit** of the therapeutic range- While technically within the therapeutic range, this leaves **minimal safety margin** in a patient who just experienced toxicity- Starting treatment immediately at this level carries higher risk of recurrent side effects*120 hours (3 half-lives)*- After 3 half-lives, the concentration would be **0.5 ng/mL**, which is **below the therapeutic range** (1-2 ng/mL)- This is overly conservative and would **unnecessarily delay** resumption of essential cardiac medication- Could lead to inadequate control of the underlying condition (heart failure or atrial fibrillation)*140-180 hours (3.5-4.5 half-lives)*- This would reduce digoxin to **0.25-0.35 ng/mL**, well below therapeutic levels- This **excessive delay** is not clinically justified and could worsen the patient's cardiac condition- No standard protocol recommends waiting this long before resuming digoxin therapy

Question 3: Variation in sensitivity of response to different doses of a drug in different individuals is obtained from?

A. Dose-response relationship (Correct Answer)
B. Therapeutic index
C. Bioavailability
D. Phase 1 clinical trials

Explanation: ***Dose-response relationship*** - The **dose-response relationship** (particularly the **graded dose-response curve**) describes how the magnitude of a drug's effect changes with different doses. - When plotted for different individuals or populations, these curves reveal **variation in sensitivity** through differences in potency (horizontal shift) and efficacy (maximum response). - This relationship helps characterize inter-individual variability in drug response and is the fundamental concept for understanding differential sensitivity. *Therapeutic index* - The **therapeutic index** is a measure of drug safety, representing the ratio between the toxic dose and the effective dose (TD50/ED50 or LD50/ED50). - It does not directly explain the variation in sensitivity to different doses among individuals, but rather provides information about the drug's overall safety margin. *Bioavailability* - **Bioavailability** refers to the fraction of an administered drug that reaches the systemic circulation unchanged. - While it influences the drug concentration at the site of action, it doesn't directly measure the variability in physiological response to that concentration among individuals. *Phase 1 clinical trials* - **Phase 1 clinical trials** are the first stage of testing a new drug in humans, primarily focusing on safety, dosage range, and pharmacokinetics in a small group of healthy volunteers. - While variability in response may be observed during these trials, they are not the *pharmacological concept* that describes this variation; rather, dose-response relationships are used to interpret findings from these trials.

Question 4: A patient on digoxin therapy presents with atrial fibrillation and controlled ventricular rate. Upon evaluation, the patient's serum digoxin levels are elevated compared to previous values. Which of the following concomitant medications is most likely to have contributed to the enhanced digoxin toxicity?

A. Triamterene
B. KCL
C. Atenolol
D. Clarithromycin (Correct Answer)
E. Amiodarone

Explanation: ***Clarithromycin*** - **Clarithromycin** is a **macrolide antibiotic** known to inhibit the cytochrome P450 3A4 (CYP3A4) enzyme system and **P-glycoprotein**. - This inhibition leads to decreased metabolism and **efflux of digoxin**, resulting in **increased serum digoxin levels** and enhanced toxicity. - Among the options, clarithromycin is the **most common cause** of elevated digoxin levels through P-gp inhibition. *Triamterene* - **Triamterene** is a **potassium-sparing diuretic** that can increase serum potassium. - **Hyperkalemia** generally *reduces* the binding of digoxin to Na+/K+-ATPase, thereby potentially *reducing* its toxic effects. - Does not significantly affect digoxin serum levels. *KCL* - **Potassium chloride (KCl)** is used to correct **hypokalemia**. - **Hypokalemia** can *potentiate* digoxin toxicity because low potassium increases digoxin binding to the Na+/K+-ATPase pump. - However, KCl supplementation *corrects* hypokalemia and would actually *reduce* toxicity risk, not increase serum digoxin levels. *Atenolol* - **Atenolol** is a **beta-blocker** primarily used to control heart rate and blood pressure. - While it can slow the heart rate like digoxin (additive pharmacodynamic effect), it does not significantly alter the **pharmacokinetics** or serum levels of digoxin. *Amiodarone* - **Amiodarone** is an **antiarrhythmic** that can inhibit P-glycoprotein and increase digoxin levels. - However, in this scenario, **clarithromycin** is more commonly associated with acute elevations in digoxin levels in clinical practice. - Amiodarone interactions are well-known and typically require dose adjustments at initiation.

Question 5: Which study design is most effective for investigating rare adverse effects of a drug?

A. Cohort study
B. Cross-sectional study
C. Case-control study (Correct Answer)
D. Clinical trial/experimental study

Explanation: ***Case-control study*** - This design starts by identifying individuals with the **rare adverse effect (cases)** and a control group without the effect to look back for exposure to the drug. - It is efficient for studying rare outcomes because it doesn't require following a large population for a long time to observe few events. *Cohort study* - A **cohort study** follows a group of individuals exposed and unexposed to a drug forward in time to observe outcomes. - While good for common outcomes, it would require an **extremely large sample size** and a long follow-up period to observe rare adverse drug effects. *Cross-sectional study* - A **cross-sectional study** assesses exposure and outcome simultaneously at a single point in time. - This design is suitable for determining **prevalence** but cannot establish temporal relationships between drug exposure and rare adverse effects, nor is it efficient for rare outcomes. *Clinical trial/experimental study* - **Clinical trials** are primarily designed to test the efficacy and safety of new interventions, usually focusing on common adverse effects. - They are generally **not powered** or long enough to detect rare adverse events, as such events would occur in very few participants, if any.

Question 6: At toxic doses, zero-order kinetics is seen in which of the following substances?

A. Phenytoin (Correct Answer)
B. Valproate
C. Carbamazepine
D. Penicillin

Explanation: ***Phenytoin*** - **Phenytoin** exhibits **zero-order kinetics** at toxic (saturating) doses because its metabolic enzymes become saturated, leading to a constant amount of drug eliminated per unit time rather than a constant fraction - This property makes its plasma concentration disproportionately increase with small dose adjustments once the enzymes are saturated, greatly increasing the risk of **toxicity** - Phenytoin is the **classic example** of capacity-limited metabolism due to saturation of hepatic enzymes (CYP2C9 and CYP2C19) *Penicillin* - Penicillin generally follows **first-order kinetics**, meaning a constant fraction of the drug is eliminated per unit time, and its elimination rate is proportional to its concentration - It is not commonly associated with zero-order kinetics even at higher doses, as its elimination pathways (renal excretion and metabolism) are typically not saturated within therapeutic or moderately toxic ranges *Valproate* - Valproate primarily follows **first-order kinetics** within its therapeutic range, with its elimination rate dependent on the drug concentration - While it can exhibit non-linear kinetics at very high concentrations due to protein binding saturation and enzyme saturation, it is less commonly cited as a classic example of zero-order kinetics compared to phenytoin *Carbamazepine* - Carbamazepine follows **first-order kinetics** within its therapeutic window - It undergoes **autoinduction** of its own metabolism, meaning that with continued dosing, its metabolic enzymes become more active, leading to increased elimination over time rather than saturation-induced zero-order kinetics

Question 7: Lidocaine is used in a loading dose for the treatment of arrhythmias. The loading dose of this drug depends upon which of the following factors?

A. Clearance
B. Volume of distribution (Correct Answer)
C. Half-life
D. Bioavailability
E. Elimination rate constant

Explanation: ***Volume of distribution*** - The **loading dose** of a drug is primarily determined by its **volume of distribution (Vd)** and the **target plasma concentration**. - A larger **Vd** means the drug distributes widely into tissues, requiring a larger loading dose to achieve the desired concentration in the central compartment. *Clearance* - **Clearance** dictates the **maintenance dose** needed to sustain a steady-state concentration once the loading dose has been administered. - It reflects the rate at which the drug is eliminated from the body, not how much is initially needed to fill the distribution volume. *Half-life* - **Half-life** determines the **time required to reach steady-state** and the **dosing interval** for maintaining therapeutic concentrations. - While related to clearance and Vd, it does not directly determine the magnitude of the initial loading dose itself. *Bioavailability* - **Bioavailability** is the fraction of administered drug that reaches the systemic circulation in an unchanged form. - It influences the oral dose required to achieve a certain plasma concentration, but the concept of loading dose is typically considered for the intravenous route where bioavailability is 100%. *Elimination rate constant* - The **elimination rate constant (ke)** describes the rate of drug elimination and is related to clearance and volume of distribution (ke = Cl/Vd). - Like clearance, it determines the **maintenance dose** and dosing frequency, not the initial loading dose required to achieve therapeutic levels.

Question 8: Therapeutic index of a drug is an indicator of its:

A. Effectiveness
B. Adverse Effects
C. Therapeutic Effect
D. Safety Profile (Correct Answer)

Explanation: ***Safety Profile*** - The **therapeutic index (TI)** is a ratio that compares the dose of a drug that produces a **toxic effect** to the dose that produces a **therapeutically desired effect**. - A higher therapeutic index generally indicates a **safer drug**, as it means a larger dose is required to cause toxic effects compared to the therapeutic dose. *Effectiveness* - While related to efficacy, effectiveness usually refers to how well a drug works in **real-world clinical practice**, not directly measured by the therapeutic index. - The therapeutic index focuses on the **margin between efficacy and toxicity**, rather than just the degree of positive response. *Adverse Effects* - The **therapeutic index** considers the toxic dose, which leads to adverse effects, but it's a measure of the **margin of safety**, not just the presence or absence of adverse effects. - It quantifies the **risk of adverse effects** relative to the therapeutic benefit, rather than simply listing or describing them. *Therapeutic Effect* - The **therapeutic index** incorporates the dose required for a therapeutic effect, but its primary purpose is to assess the **risk of toxicity** in relation to that therapeutic effect. - It's a measure of the **balance between benefit and harm**, not solely the therapeutic benefit itself.

Question 9: Nystagmus is associated with all except:

A. Vestibular disease
B. Cochlear disease (Correct Answer)
C. Arnold-Chiari malformation
D. Cerebellar disease

Explanation: ***Cochlear disease*** - **Cochlear disease** primarily affects **hearing** through damage to the cochlea, the auditory part of the inner ear [3]. - It does not directly involve the vestibular system, which controls balance and eye movements, and therefore is not associated with nystagmus. *Vestibular disease* - **Vestibular disease** affects the **balance system** of the inner ear and can cause nystagmus, often accompanied by vertigo and dizziness [2], [4]. - Examples include **benign paroxysmal positional vertigo (BPPV)**, **Meniere's disease**, and **vestibular neuronitis**. *Arnold-Chiari malformation* - **Arnold-Chiari malformation** involves structural defects in the cerebellum and brainstem, which can disrupt the normal control of eye movements. - This often leads to **downbeat nystagmus** or other forms of central nystagmus due to compression of the **brainstem** and **cerebellum**. *Cerebellar disease* - The **cerebellum** plays a crucial role in coordinating smooth eye movements and maintaining gaze stability. - **Cerebellar disease** can cause various types of nystagmus, such as **gaze-evoked nystagmus** and **rebound nystagmus**, due to impaired motor control [1].

Question 10: Which one of the following causes low-volume erythrocytosis?

A. High altitude
B. Polycythemia Rubra Vera
C. Gaisbock's syndrome (Correct Answer)
D. Exogenous testosterone therapy

Explanation: ***Gaisbock's syndrome*** - **Gaisbock's syndrome**, also known as **stress erythrocytosis** or **relative polycythemia**, is characterized by a high hematocrit due to reduced plasma volume rather than an absolute increase in red blood cell (RBC) mass. - It is often associated with **hypertension**, **obesity**, and **stress**, predominantly affecting middle-aged men with a normal total erythrocyte mass [1]. *High altitude* - Living at **high altitudes** can cause **secondary erythrocytosis** due to chronic hypoxia, leading to increased erythropoietin production and an absolute increase in red blood cell mass [2]. - This is a **true erythrocytosis**, where both red blood cell count and total blood volume are elevated. *Polycythemia Rubra Vera* - **Polycythemia vera** is a **myeloproliferative neoplasm** causing an absolute increase in the red blood cell mass, resulting from uncontrolled production by the bone marrow. - It is characterized by a **JAK2V617F mutation** and leads to increased total blood volume, not reduced plasma volume [1]. *Exogenous testosterone therapy* - **Exogenous testosterone therapy** can stimulate erythropoiesis, leading to an **increase in red blood cell mass** and hematocrit, which is a form of **secondary erythrocytosis**. - This effect is mediated by increased erythropoietin production and is an absolute increase in RBCs, not a low-volume condition.

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free